Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Selling, General & Admin	14.25
Research & Development	81.01
Operating Expenses	95.26
Operating Income	-95.26
Interest Expense	-1.6
Interest & Investment Income	6.4
Other Non Operating Income (Expenses)	0
EBT Excluding Unusual Items	-90.46
Other Unusual Items	-0.87
Pretax Income	-91.34
Net Income	-91.34
Preferred Dividends & Other Adjustments	-20.39
Net Income to Common	-70.95
Shares Outstanding (Basic)	17
Shares Outstanding (Diluted)	17
EPS (Basic)	-4.23
EPS (Diluted)	-4.23
Free Cash Flow	-63.3
Free Cash Flow Per Share	-3.77
EBITDA	-95.23
D&A For EBITDA	0.03
EBIT	-95.26

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q